4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Current Deferred Revenue of $360000.0 for Q1 2026, down 58.43% year-over-year from $866000.0 in Q1 2025, and little changed quarter-over-quarter from $360000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Current Deferred Revenue for 8 consecutive years, with $360000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 58.43% year-over-year to $360000.0; the TTM figure through Mar 2026 stood at $360000.0 (down 58.43% YoY), while the FY2025 annual figure was $360000.0, up 40.08% from the prior year.
- Current Deferred Revenue was little changed at $360000.0 in Q1 2026 per FDMT's latest filing, from $360000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $3.9 million in Q1 2022 and bottomed at $257000.0 in Q4 2024.
- Historically, Current Deferred Revenue has averaged $1.2 million across 5 years, with a median of $1.2 million in 2023.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue slumped 86.07% — and 2024, when it jumped 69.92%.
- 4D Molecular Therapeutics' Current Deferred Revenue stood at $2.0 million in 2022, then plunged by 86.07% to $273000.0 in 2023, then declined by 5.86% to $257000.0 in 2024, then surged by 40.08% to $360000.0 in 2025, then changed by 0.0% to $360000.0 in 2026.
- Business Quant data shows FDMT's Current Deferred Revenue at $360000.0 in Q1 2026, $360000.0 in Q4 2025, and $360000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 360,000.00 |
| Mar 31, 2026 | 360,000.00 |
| Dec 31, 2025 | 360,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 866,000.00 |
| Dec 31, 2024 | 257,000.00 |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 1.23 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 778,000.00 |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 2.21 Mn |
| Jun 30, 2022 | 2.26 Mn |
| Mar 31, 2022 | 3.87 Mn |
| Dec 31, 2021 | 5.09 Mn |
| Sep 30, 2021 | 4.74 Mn |